Tildrakizumab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Tildrakizumab. Educational only — not medical advice.
Labeled uses
ILUMYA® is indicated for the treatment of moderate-to-severe plaque psoriasis in aduts who are candidates for systemic therapy or phototherapy.
Source: FDA labeling via NIH DailyMed (set c6a322bb…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.